This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via ISI Web of Science (30)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Metry, D. W.
Right arrow Articles by Levy, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Metry, D. W.
Right arrow Articles by Levy, M. L.
Related Collections
Right arrow Allergy & Dermatology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
PEDIATRICS Vol. 112 No. 6 December 2003, pp. 1430-1436

EXPERIENCE AND REASON

Use of Intravenous Immunoglobulin in Children With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Seven Cases and Review of the Literature

Denise W. Metry, MD*,{ddagger}, Peter Jung, MD{ddagger} and Moise L. Levy, MD*,{ddagger}

* Departments of Dermatology
{ddagger} Pediatrics, Texas Children’s Hospital, Baylor College of Medicine, Houston, Texas

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis are the most severe cutaneous reactions that occur in children. Off-label use of human intravenous immunoglobulin (IVIG) has been reported in a number of autoimmune and cell-mediated blistering disorders of the skin, including severe cutaneous drug reactions. We review 28 previous reports in which IVIG was used in pediatric patients with SJS and toxic epidermal necrolysis and discuss our experience in 7 children with SJS, in whom no new blisters developed within 24 to 48 hours after IVIG administration and rapid recovery ensued. IVIG seems to be a useful and safe therapy for children with severe cutaneous drug reactions. Well-controlled, prospective, multicenter clinical trials are needed to determine optimal dosing guidelines and to compare the efficacy and safety of IVIG with other potentially effective modalities.

Key Words: Stevens-Johnson syndrome • toxic epidermal necrolysis • intravenous immunoglobulin • IVIG

Abbreviations: SJS, Stevens-Johnson syndrome • TEN, toxic epidermal necrolysis • IVIG, intravenous immunoglobulin

Received for publication Jul 12, 2002; Accepted Apr 4, 2003.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Arch Pediatr Adolesc MedHome page
Picture of the Month--Diagnosis
Arch Pediatr Adolesc Med, August 1, 2006; 160(8): 802 - 802.
[Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
N Powell, J M Munro, and D Rowbotham
Colonic involvement in Stevens-Johnson syndrome.
Postgrad. Med. J., June 1, 2006; 82(968): e10 - e10.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
P. K. Young, S. Y. Ruggeri, S. Galbraith, and B. A. Drolet
Vesicular eczema after intravenous immunoglobulin therapy for treatment of stevens-johnson syndrome.
Arch Dermatol, February 1, 2006; 142(2): 247 - 248.
[Full Text] [PDF]

Home page
 Journal Watch DermatologyHome page
Use of IVIG in Children with SJS and TEN
Journal Watch Dermatology, February 4, 2004; 2004(204): 2 - 2.
[Full Text]

eLetters:

Read all eLetters

Intravenous immunoglobulin in toxic epidermal necrolysis
Srdjan Pasic
Pediatrics Online, 9 Jan 2004 [Full text]